A phase III trial to evaluate pimavanserin for the treatment of hallucinations and delusions associated with dementia-related psychosis

Trial Profile

A phase III trial to evaluate pimavanserin for the treatment of hallucinations and delusions associated with dementia-related psychosis

Recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Oct 2017

At a glance

  • Drugs Pimavanserin (Primary)
  • Indications Delusions; Hallucinations
  • Focus Registrational; Therapeutic Use
  • Acronyms HARMONY
  • Sponsors Acadia Pharmaceuticals
  • Most Recent Events

    • 06 Oct 2017 New trial record
    • 04 Oct 2017 According to a company media release, ACADIA believes that robust positive results from one Phase III study together with supportive data from prior studies with pimavanserin could serve as the basis of a supplementary New Drug Application (sNDA) for the treatment of hallucinations and delusions associated with dementia-related psychosis.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top